The ten targeted genes that were coupled with IL6 as the core can be used for HXL131 therapy, with DUSP1 and TNFSF9 as the critical targets for regulation, thus laying the foundation and possibility for their use in the targeted therapy of PCa. This evidence concerns the gene IL6 and posterior cortical atrophy.